Elgqvist J, Bernhardt P, Hultborn R, et al. Myelotoxicity and RBE of At-211-conjugated monoclonal antibodies compared with Tc-99m-conjugated monoclonal antibodies and Co-60 irradiation in nude mice[J]. J Nucl Med, 2005, 46: 464-471.
[2]
Elgqvist J, Andersson H, Tom B, et al. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(abV)2:therapeutic efficacy and myelotoxicity[J]. Nucl Med Biol, 2006, 33: 1 065-1 072.
[3]
Elgqvist J, Andersson H, Back T, et al. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with At-211-labeled monoclonal antibody MX35[J]. J Nucl Med, 2005, 46(11): 1 907-1 915.
[4]
Back T, Andersson H, Divgi CR, et al. At-211 radioimmunotherapy of subcutaneous human ovarian cancer xenografts: Evaluation of relative biologic effectiveness of an alpha-emitter in vivo[J]. J Nucl Med, 2005, 46: 2 061-2 067.
[5]
Akabani G, Carlin S, Welsh P, et al. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneityon survival fraction[J]. Nucl Med Biol, 2006, 33: 333-347.
[6]
Abraham BA, McLendona RE, Okamuraa T, et al. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of α-particleemitting 211At-labeled trastuzumab[J]. Nucl Med Biol, 2009, 36: 659-669.
[7]
Palm S, Bck T, Claesson I, et al. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice[J]. International Journal of Radiation Oncology Biology Physics, 2007, 69(2): 572-579.
[8]
Zhang Z, Zhang ML, Garmestani K, et al. Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25[J]. Blood, 2006, 108(3): 1 007-1 012.
[9]
Petrich T, Korkmaz Z, Krull D, et al. In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37(5): 851-861.
[10]
Almqvist Y, Steffen AC, Lundqvist H. Biodistribution of At-211-Labeled humanized monoclonal antibody A33[J]. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22(4): 480-487.
[11]
Zalutsky MR, Reardon DA, Akabani G, et al. Clinical Experience with a-particle-emitting-211At: Treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6[J]. J Nucl Med, 2008, 49: 30-38.
[12]
Andersson H, Cederkrantz E, Back T, et al. Intraperitoneal a-particle radioimmunotherapy of ovarian cancer patients: Pharmacokinetics and dosimetry of 211At-MX35 F(ab’)2—a phase Ⅰ study[J]. J Nucl Med, 2009; 50: 1 153-1 160.
[13]
Liu BL, Jin YT, Liu ZH, et al. Halogen exchanges using crown ethers: synthesis and preliminary is distribution of 6-(211At)-astato-methyl-19-norcholest-5 (10) -en-3β2-ol[J]. Int J App l Radiat Isot, 1985, 36: 561.
[14]
Liu N, Jin JN, Mo SW, et al. Prepartion and prerliminary evaluation of astatine-211 labeled IgG via DTPA anhydride [J]. J Radioanal Nucl Chem, 1998, 227: 187-190.
[15]
Liu N, Jin JN, Zhang SY, et al. 211At labeling of a monoclonal antibody and its Fab fragment: Cytotoxicity on human gastric cancer and biodistribution in nude mice with tumor exnografts[J]. J Radioanal Nucl Chem, 2001, 247(1): 129-133.
[16]
Liu N, Jin JN, Zhang SY, et al. Astatine211 labeling of monoclonal antibody and its fab fragment: Synthesis, immunoreactivity and expermental therapy[J]. J Lablled Comp Radiopharm, 1995, 36: 1 105-1 113.
Yang YY, Lin RS, Liu N, et al. Astatine211 labeling of protein using TCP as a bifunctional linker: synthesis and preliminary evaluation in vivo and in vitro[J]. J Radioanal and Nucl Chem, 2011, 288(1): 71-77.
[19]
Yang YY, Liu N, Zan LB, et al. Radioiodination of insulin using N-succinimidyl 5-(tributylstannyl)-3-pyridinecarboxylate (SPC) as a bi-functional linker: Synthesis and biodistribution in mice[J]. J Radioanal and Nucl Chem, 2006, 268 (2 ): 205-210.
[20]
Liu N, Yang YY, Jin JN, et al. Astatine-211 labeling of insulin: Synthesis and preliminary evaluation in vivo and in vitro[J]. J Radioanal and Nucl Chem, 2007, 272(1): 85-90.
[21]
Yang YY, Liu N, Liao JL, et al. Preparation and preliminary evaluation of 211At labeled amidobisphophonates[J]. J Radioanal and Nucl Chem, 2010, 283(2): 329-335.
[22]
Weinreich R. Molecular radiotherapy with 211At[M]//Amaldi U, Larsson B, Lemoigne Y, Eds. Advance in Hadrontherapy. Holland：Elsevier Science, Amsterdam, 1997: 359-382.
[23]
Brown I. Astatine radiopharmaceuticals Astatine-211: Its possible applications in cancer therapy[J]. Appl Radiat Isot, 1986, 37: 789-798.
[24]
Link EM, Michalowski AS, Rsch F. 211At-methylene blue for targeted radiotherapy of disseminated melanoma: microscopic analysis of tumour versus normal tissue damage[J]. Eur J Cancer, 1996, 32A: 1 986-1 994.
[25]
Vaidyanathan G, Friedman HS, Keir ST, et al. Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model[J]. Nucl Med Biol, 1996, 23: 851-856.
[26]
Lindegren S, Andersson H, Jacobsson L, et al. Synthesis and biodistribution of 211At-labeled,biotinylated,and chargemodified poly-L-lysine: Evaluation for use as an effector molecule in pretargeted intraperitoneal tumor therapy[J]. Bioconjugate Chem, 2002, 13: 502-509.
[27]
Murud KM, Larsen RH, Hoff P, et al. Synthesis, purification and stability testing of novel 211At-and 125I-labeled amidbisphosphonates[J]. Nucl Med Biol, 1999, 26: 397-403.
[28]
Wilbur DS, Vessella RL, Stray JE, et al. Preparation and evaluation of para-[211At]astatobenzoyl labeled anti-renal cell carcinoma antibody A6HF(ab’)2 In vivo distribution comparison with para-[125I]iodobenzoyl labeled A6HF(ab’)2[J]. Nucl Med Biol, 1993, 20: 917-927.
[29]
Zalutsky MR, McLendon RE, Garg PK, et al. Radioimmunotherapy of neoplastic meningitis in rats using an α-particle emitting radioimmunoconjugates[J]. Cancer Res, 1994, 54: 4 719-4 725.
[30]
Zalutsky MR, Stabin MG, Larsen RH, et al. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an α-particle-emitting immunoconjugate[J]. Nucl Med Biol, 1997, 24: 255-262.
[31]
Yordanov AT, Garmestani K, Zhang M, et al. Preparation and in vivo evaluation of linkers for 211At labeling of humanized ant-Tac[J]. Nucl Med Biol, 2001, 28: 845-856.
[32]
Zalustky MR, Cokfgor I, Akabani G. Phase Ⅰtrial of alpha-particle-emitting astatine-211 labeled chimeric anti-tenascin antibody in recurrent malignant glioma patients [abstract] [J]. Proc Am Assoc Cancer Res, 2000, 41: 544-549.
Zona C, Bonardi ML, Groppi F, et al. Wet-chemistry method for the separation of no-carrier-added 211At/ 211Po from 209Bi target irradiated by alpha-beam in cyclotron[J]. J Radioanal and Nucl Chem, 2008, 276(3): 819-824.
[35]
Yordanov AT, Pozzi O, Carlin S, et al. Wet harvesting of no-carrier-added 211At from an irradiated 209Bi target for radiopharmaceutical applications[J]. J Radioanal and Nucl Chem, 2004, 262(3): 593-599.
[36]
Moumita M, Susanta L. Theoretical approach to explore the production routes of astatine radionuclides[J]. Physical Review C, 2009, 79(2): 024611.
[37]
Zalutsky MR, Reardon DA, Pozzi OR, et al. Targeted a particle radiotherapy with 211At-labeled monoclonal antibodies [J]. Nucl Med Biol, 2007, 34: 779-785.
[38]
Vaidyanathan G, Affleck DJ, Schottelius M, et al. Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and 211At via a tin precursor[J]. Bioconjugate Chem, 2006, 17: 195-203.
[39]
Wilbur DS, Thakar MS, Hamlin DK, et al. Reagents for astatination of biomolecules. 4: comparison of maleimido-closo-decaborate(2-) and meta-[211At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [211At]astatine[J]. Bioconjugate Chem, 2009, 20: 1 983-1 991.
[40]
Pruszyn SM, Bilewicz A, Zalutsky MR. Preparation of Rh[16aneS4-diol] 211At and Ir[16aneS4-diol] 211At complexes as potential precursors for astatine radiopharmaceuticals. part I: Synthesis[J]. Bioconjugate Chem, 2008, 19: 958-965.
[41]
Talanova VS, Garmestanib K, Regino CAS. Preparation and in vivo evaluation of a novel stabilized linker for 211At labeling of protein[J]. Nucl Med Biol, 2006, 33: 469-480.
[42]
Walte A, Sriyapureddy SSR, Korkmaz Z. Preparation and evaluation of At-211 labelled antineoplastic antibodies[J]. Journal of Pharmacy and Pharmaceutical Sciences, 2007, 10(2): 277-285.
[43]
Bourgeois M, Guerard F, Alliot C. Feasibility of the radioastatination of a monoclonal antibody with astatine-211 purified by wet extraction[J]. J Lablled Comp Radiopharm, 2008, 51(11-12): 379-383.
[44]
Jan KB, Martin HC, Kona K， et al. Astatination of nanoparticles containing silver as possible of 211At [J]. Appl Radiat Isot, 2006, 64: 201-206.
[45]
Persson MI, Gedda L, Jensen HJ, et al. Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours[J]. Oncology Reports, 2006, 15: 673-680.
[46]
Hawthorne MF, Maderna A. Applications of radiolabeled boron clusters to the diagnosis and treatment of cancer[J]. Chem Rev, 1999, 99: 3 421-3 434.
[47]
Wilbur DS, Chyan MK, Hamlin DK, et al. Reagents for astatination of biomolecules 2: conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination[J]. Bioconjugate Chem, 2007, 18: 1 226-1 240.
[48]
Steffen AC, Almqvist Y, Chyan MK, et al. Biodistribution of 211At labeled HER-2 binding affibody molecules in mice[J]. Oncology Reports, 2007, 17: 1 141-1 147.
[49]
Pozzi OR, Zalutsky MR. Radiopharmaceutical chemistry of targeted radiotherapeutics. Part 1: Effects of solvent on the degradation of radiohalogenation precursors by At-211 alpha-particles[J]. J Nucl Med, 2005, 46(4): 700-706.
[50]
Pozzi OR, Zalutsky MR. Radiopharmaceutical chemistry of targeted radiotherapeutics. Part 3: Alpha-particle-induced radiolytic effects on the chemical behaviour of At211[J]. J Nucl Med, 2007, 48: 1 190-1 196.
